Onconova appoints James Marino board

Newtown, Pennsylvania-based Onconova Therapeutics, a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, has named James J Marino to its board of directors. Mr Marino was a partner at the global law firm of Dechert for 28 years where he was managing partner of the Princeton office. During this period, he advised numerous leading life science companies in connection with financings, acquisitions and strategic alliances. He served as the outside counsel for Onconova from its inception through and including its initial public offering. Previously, he was on the board of Pharmacopeia Drug Discovery from 2000-2006 and has worked in advisory capacities and on the boards of multiple non-profit organizations, including Robert Wood Johnson University Hospital.

Newtown, Pennsylvania-based Onconova Therapeutics, a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, has named James J Marino to its board of directors. Mr Marino was a partner at the global law firm of Dechert for 28 years where he was managing partner of the Princeton office. During this period, he advised numerous leading life science companies in connection with financings, acquisitions and strategic alliances. He served as the outside counsel for Onconova from its inception through and including its initial public offering. Previously, he was on the board of Pharmacopeia Drug Discovery from 2000-2006 and has worked in advisory capacities and on the boards of multiple non-profit organizations, including Robert Wood Johnson University Hospital.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Anticancer

Gilead Set To Expand Trodelvy/Keytruda Into Frontline TNBC

 

The company reported positive topline results for ASCENT-04, which also bode well for the ASCENT-03 trial in patients with low PD-L1 expression.

Enhertu Takes The First-Line Throne In HER2 Metastatic Breast Cancer

 

AstraZeneca and Daiichi’s DESTINY-Breast09 trial testing Enhertu with pertuzumab versus standard of care showed a statistically significant and meaningful PFS improvement.

Oncology’s Most Eligible Unpartnered Assets

 

Evaluate's top five unpartnered clinical oncology assets reveals you have to get in early to snap up innovation in the competitive cancer space.

In Brief: BriaCell’s Breast Cancer Cell Therapy Boosts Survival In Phase II

 

BriaCell announced its cell therapy Bria-IMT plus checkpoint inhibitors bested Gilead’s Trodelvy in a Phase II trial in HR+ breast cancer; a Phase III trial is enrolling.

More from Therapy Areas

Seven Up For Sanofi and Regeneron With Dupixent CSU Approval

 
• By 

The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.

Lilly Scores With Orforglipron In Diabetes, Generating Excitement For Obesity

 

The company announced positive topline results for the oral GLP-1 drug in type 2 diabetes that beat expectations.

In Brief: BriaCell’s Breast Cancer Cell Therapy Boosts Survival In Phase II

 

BriaCell announced its cell therapy Bria-IMT plus checkpoint inhibitors bested Gilead’s Trodelvy in a Phase II trial in HR+ breast cancer; a Phase III trial is enrolling.